Search

Searching. Please wait…

New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Abstract: Non-small cell lung cancer (NSCLC) presents the greatest number of identified therapeutic targets, some of which have therapeutic utility. Currently, detecting EGFR, BRAF, KRAS and MET mutations, ALK, ROS1, NTRK and RET translocations, and PD-L1 expression in these patients is considered essential. The use of next-generation sequencing facilitates precise molecular diagnosis and allows the detection of other emerging mutations, such as the HER2 mutation and predictive biomarkers for immunotherapy responses. In this consensus, a group of experts in the diagnosis and treatment of NSCLC selected by the Spanish Society of Pathology and the Spanish Society of Medical Oncology have evaluated currently available information and propose a series of recommendations to optimize the detection and use of biomarkers in daily clinical practice

 Autoría: Isla D., Lozano M.D., Paz-Ares L., Salas C., de Castro J., Conde E., Felip E., Gómez-Román J., Garrido P., Enguita A.B.,

 Fuente: Clinical and Translational Oncology, 2023, 25, 1252-1267 - (CORRECTION) 2023, 25, 1488

 Editorial: Springer-Verlag Italia

 Año de publicación: 2023

 Nº de páginas: 16

 Tipo de publicación: Artículo de Revista

 DOI: 10.1007/s12094-022-03046-9

 ISSN: 1699-048X,1699-3055

 Url de la publicación: https://doi.org/10.1007/s12094-022-03046-9

Authorship

ISLA, DOLORES

LOZANO, MARIA D.

PAZ-ARES, LUIS

SALAS, CLARA

CASTRO, JAVIER DE

CONDE, ESTHER

FELIP, ENRIQUETA

GARRIDO, PILAR

ENGUITA, ANA BELÉN